Jennifer M VanNatta, Graham J Carlson, Haichan Niu, Ruoli Bai, Hashini I Wanniarachchi, Regan Schuetze, Mary Lynn Trawick, Ernest Hamel, Ralph P Mason, Kevin G Pinney
{"title":"苯并亚苯胺和四环类似物作为微管蛋白聚合的秋水仙碱位点抑制剂。","authors":"Jennifer M VanNatta, Graham J Carlson, Haichan Niu, Ruoli Bai, Hashini I Wanniarachchi, Regan Schuetze, Mary Lynn Trawick, Ernest Hamel, Ralph P Mason, Kevin G Pinney","doi":"10.1021/acsmedchemlett.5c00129","DOIUrl":null,"url":null,"abstract":"<p><p>Colchicine site inhibitors of tubulin polymerization function as antiproliferative anticancer agents, with certain inhibitors demonstrating a dual mechanism of action as tumor-selective vascular disrupting agents (VDAs). Our previous studies yielded potent benzosuberene-based colchicine site inhibitors of tubulin polymerization. To expand structure-activity correlations, the seven-membered fused ring and the pendant ring were modified to generate a series of new compounds, 11 being strong inhibitors (IC<sub>50</sub> ≤ 5 μM) of tubulin polymerization. Structural modifications introduced a second benzylic olefin and, separately, a nitrogen atom to the fused seven-membered ring, along with conversion to unique tetracyclic fused ring systems. Two of the active inhibitors were synthetically converted to corresponding phosphate prodrug salts to increase aqueous solubility for <i>in vivo</i> studies. In a preliminary study of VDA efficacy, these prodrugs caused blood flow disruption in mice, as revealed by bioluminescence imaging with histological confirmation. The most effective analogues from this series offer promise as cancer therapeutic agents.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1098-1107"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169467/pdf/","citationCount":"0","resultStr":"{\"title\":\"Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.\",\"authors\":\"Jennifer M VanNatta, Graham J Carlson, Haichan Niu, Ruoli Bai, Hashini I Wanniarachchi, Regan Schuetze, Mary Lynn Trawick, Ernest Hamel, Ralph P Mason, Kevin G Pinney\",\"doi\":\"10.1021/acsmedchemlett.5c00129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Colchicine site inhibitors of tubulin polymerization function as antiproliferative anticancer agents, with certain inhibitors demonstrating a dual mechanism of action as tumor-selective vascular disrupting agents (VDAs). Our previous studies yielded potent benzosuberene-based colchicine site inhibitors of tubulin polymerization. To expand structure-activity correlations, the seven-membered fused ring and the pendant ring were modified to generate a series of new compounds, 11 being strong inhibitors (IC<sub>50</sub> ≤ 5 μM) of tubulin polymerization. Structural modifications introduced a second benzylic olefin and, separately, a nitrogen atom to the fused seven-membered ring, along with conversion to unique tetracyclic fused ring systems. Two of the active inhibitors were synthetically converted to corresponding phosphate prodrug salts to increase aqueous solubility for <i>in vivo</i> studies. In a preliminary study of VDA efficacy, these prodrugs caused blood flow disruption in mice, as revealed by bioluminescence imaging with histological confirmation. The most effective analogues from this series offer promise as cancer therapeutic agents.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"16 6\",\"pages\":\"1098-1107\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169467/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acsmedchemlett.5c00129\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/12 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsmedchemlett.5c00129","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.
Colchicine site inhibitors of tubulin polymerization function as antiproliferative anticancer agents, with certain inhibitors demonstrating a dual mechanism of action as tumor-selective vascular disrupting agents (VDAs). Our previous studies yielded potent benzosuberene-based colchicine site inhibitors of tubulin polymerization. To expand structure-activity correlations, the seven-membered fused ring and the pendant ring were modified to generate a series of new compounds, 11 being strong inhibitors (IC50 ≤ 5 μM) of tubulin polymerization. Structural modifications introduced a second benzylic olefin and, separately, a nitrogen atom to the fused seven-membered ring, along with conversion to unique tetracyclic fused ring systems. Two of the active inhibitors were synthetically converted to corresponding phosphate prodrug salts to increase aqueous solubility for in vivo studies. In a preliminary study of VDA efficacy, these prodrugs caused blood flow disruption in mice, as revealed by bioluminescence imaging with histological confirmation. The most effective analogues from this series offer promise as cancer therapeutic agents.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.